Overview

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Combination of GSK573719 and GW642444 in Subjects With COPD

Status:
Completed
Trial end date:
2010-04-20
Target enrollment:
Participant gender:
Summary
The study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of the combination of inhaled GSK573719 and GW64244 compared to placebo, in subjects with COPD.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline